Arbutus Biopharma Corp.

Arbutus Biopharma is a clinical‑stage biotech focused on novel therapies for chronic hepatitis B, featuring its subcutaneous RNAi candidate Imdusiran (Phase 1/2a) and oral PD‑L1 inhibitor AB‑101, backed by Alnylam partnership.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 44
HQ: Warminster

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
ABUS	Arbutus Biopharma Corp. Cap: 0.9B	EQUITY	NMS	USD	CA03879J1003	Active	📈